NR4A1 and breast cancer: In our study, we established an age-related gene expression signature (6GPS) and assessed whether this provided added prognostic value to the 21-gene Oncotype Dx recurrence score, a commercially available gene expression assay able to present prognostic information in hormone-receptor-positive BC.